Nexstim Oyj (FRA:5NX) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5NX Nexstim Oyj FRA:5NX
69 GF Score
Price €9.78
GF Value €9.65
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Nexstim Oyj FFO?

FFO (Funds from operations) only applies to REITs.

FRA:5NX
69GF Score
Nexstim Oyj FRA:5NX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nexstim Oyj (FRA:5NX) Overvalued in 2026?

Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued. The current stock price of €9.78 is trading 1.3% above its estimated GF Value™ of €9.65. GuruFocus considers Nexstim Oyj to be Fairly Valued.

Key valuation signals for FRA:5NX:

  • FFO:
  • GF Value™: €9.65 vs. price of €9.78 (1.3% above fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the FRA:5NX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nexstim Oyj Business Description

Other Exchanges NXTMH:Finland
Address Elimaenkatu 9 B, Helsinki, FIN, 00510
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
69GF Score

Get the complete analysis for FRA:5NX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.78
Price
€9.65
GF Value